India's Dr Reddy's snaps up some UCB brands in South Asia for $128.3M

Dr. Reddy's Laboratories said it has agreed to buy some brands of UCB for 8 billion rupees ($128.3 million) in India, Nepal, Sri Lanka and Maldives, making a side deal as part of a broader growth drive in manufacturing and injectables.

The revenues from these brands notched up to around 1.5 billion rupees in 2014, the Indian generic drug maker said.

The acquisition of UCB's existing drugs in dermatology, respiratory and pediatrics diseases will further expand Dr. Reddy's footprint in these fast growth areas, the company said.

Dr. Reddy's expects to close the deal in the first quarter of fiscal 2016.

- here's the release release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.